675 related articles for article (PubMed ID: 18413443)
1. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
[TBL] [Abstract][Full Text] [Related]
5. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Ilowite NT; Wallace CA; Chon Y; Lin SL; Baumgartner SW; Giannini EH;
Arthritis Rheum; 2008 May; 58(5):1496-504. PubMed ID: 18438876
[TBL] [Abstract][Full Text] [Related]
7. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
8. The German etanercept registry for treatment of juvenile idiopathic arthritis.
Horneff G; Schmeling H; Biedermann T; Foeldvari I; Ganser G; Girschick HJ; Hospach T; Huppertz HI; Keitzer R; Küster RM; Michels H; Moebius D; Rogalski B; Thon A;
Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
[TBL] [Abstract][Full Text] [Related]
9. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
[TBL] [Abstract][Full Text] [Related]
10. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
Otten MH; Prince FH; Twilt M; van Rossum MA; Armbrust W; Hoppenreijs EP; Kamphuis S; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Ten Cate R; van Suijlekom-Smit LW
J Rheumatol; 2010 Mar; 37(3):665-7. PubMed ID: 20080910
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of etanercept in the treatment of juvenile idiopathic arthritis].
de Inocencio Arocena J; Merino Muñoz R; Alvarez Madrid C; García-Consuegra Molina J
An Pediatr (Barc); 2009 Apr; 70(4):354-61. PubMed ID: 19324597
[TBL] [Abstract][Full Text] [Related]
12. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
[TBL] [Abstract][Full Text] [Related]
14. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
15. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.
Prince FH; de Bekker-Grob EW; Twilt M; van Rossum MA; Hoppenreijs EP; ten Cate R; Koopman-Keemink Y; Gorter SL; Raat H; van Suijlekom-Smit LW
Rheumatology (Oxford); 2011 Jun; 50(6):1131-6. PubMed ID: 21278067
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
Anink J; Otten MH; Prince FH; Hoppenreijs EP; Wulffraat NM; Swart JF; ten Cate R; van Rossum MA; van den Berg JM; Dolman KM; Koopman-Keemink Y; Armbrust W; Kamphuis S; van Pelt PA; Gorter SL; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
Minden K; Niewerth M; Zink A; Seipelt E; Foeldvari I; Girschick H; Ganser G; Horneff G
Rheumatology (Oxford); 2012 Aug; 51(8):1407-15. PubMed ID: 22447885
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
Lovell DJ; Giannini EH; Reiff A; Jones OY; Schneider R; Olson JC; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Lange M; Finck BK; Burge DJ;
Arthritis Rheum; 2003 Jan; 48(1):218-26. PubMed ID: 12528122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
